Terms: = Sarcomas AND PR, PGR, progesterone receptor AND Treatment
376 results:
1. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
2. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Sholler GLS; Bergendahl G; Lewis EC; Kraveka J; Ferguson W; Nagulapally AB; Dykema K; Brown VI; Isakoff MS; Junewick J; Mitchell D; Rawwas J; Roberts W; Eslin D; Oesterheld J; Wada RK; Pastakia D; Harrod V; Ginn K; Saab R; Bielamowicz K; Glover J; Chang E; Hanna GK; Enriquez D; Izatt T; Halperin RF; Moore A; Byron SA; Hendricks WPD; Trent JM
Genome Med; 2024 Feb; 16(1):28. PubMed ID: 38347552
[TBL] [Abstract] [Full Text] [Related]
3. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract] [Full Text] [Related]
4. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
5. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review.
Serbest Ceylanoglu K; Guneri Beser B; Singalavanija T; Juntipwong S; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):18-29. PubMed ID: 38241616
[TBL] [Abstract] [Full Text] [Related]
6. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study.
Kotowicz B; Dańska-Bidzińska A; Fuksiewicz M; Nasierowska-Guttmejer A; Raczkiewicz D; Gujski M; Piątek S; Bidziński M
Med Sci Monit; 2023 Dec; 29():e941562. PubMed ID: 38058118
[TBL] [Abstract] [Full Text] [Related]
8. Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.
Hwang JR; Cho YJ; Ryu JY; Choi JY; Choi JJ; Sa JK; Kim HS; Lee JW
Biomed Pharmacother; 2023 Dec; 168():115792. PubMed ID: 37924789
[TBL] [Abstract] [Full Text] [Related]
9. Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study.
Stacchiotti S; Baldi GG; Frezza AM; Morosi C; Greco FG; Collini P; Barisella M; Dagrada GP; Zaffaroni N; Pasquali S; Gronchi A; Huang P; Ingrosso M; Tinè G; Miceli R; Casali PG
Eur J Cancer; 2023 Dec; 195():113391. PubMed ID: 37918286
[TBL] [Abstract] [Full Text] [Related]
10. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract] [Full Text] [Related]
11. Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report.
Li J; Ren M; Bi F; Chen Y; Li Z
Front Immunol; 2023; 14():1228653. PubMed ID: 37691960
[TBL] [Abstract] [Full Text] [Related]
12. A multicenter retrospective analysis of clinical outcomes of intracranial chondrosarcoma in 26 patients.
Liu H; Li Z; Xue Y; Zhao T; Wu Y
Sci Rep; 2023 Sep; 13(1):14647. PubMed ID: 37669996
[TBL] [Abstract] [Full Text] [Related]
13. Case Report: Immunotherapy for low-grade myofibroblastic sarcoma of the pharynx.
Sun B; Luo Z; Liu P; He Y; He S; Liu W
Front Immunol; 2023; 14():1190210. PubMed ID: 37469511
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract] [Full Text] [Related]
15. Intrathoracic synovial sarcoma with BRAF V600E mutation.
Russo I; Barresi S; Di Paolo PL; Di Ruscio V; Del Baldo G; Serra A; Vallese S; Miele E; Mastronuzzi A; Alaggio R; Ferrari A; Milano GM
Oncotarget; 2023 Jul; 14():703-708. PubMed ID: 37417899
[TBL] [Abstract] [Full Text] [Related]
16. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract] [Full Text] [Related]
17. [Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group].
Karabajakian A; Genestie C; Meeus P; Guyon F; Llacer Moscardo C; Croce S; Taieb S; Duffaud F; Pautier P; Ray-Coquard I; Blay JY
Bull Cancer; 2023; 110(7-8):836-843. PubMed ID: 37202293
[TBL] [Abstract] [Full Text] [Related]
18. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M; Fava P; Stanganelli I; Ribero S; Pigozzo J; Di Giacomo AM; Ridolfi L; Tronconi MC; Trojaniello C; Bersanelli M; Garutti M; Indini A; De Risi I; De Tursi M; Merelli B; Morgese F; Occelli M; Cappellini GCA; Poletto S; Fedele D; Brugnara S; Frisinghelli M; Formisano L; Conca R; Tucci M; Russillo M; Ceroni L; Queirolo P; Targato G; Strippoli S; Mandalà M; Guida M; Quaglino P
Eur J Cancer; 2023 Jul; 187():25-35. PubMed ID: 37099946
[TBL] [Abstract] [Full Text] [Related]
19. A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma.
Kelly CM; Qin LX; Whiting KA; Richards AL; Avutu V; Chan JE; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Adamson T; Singer S; Bartlett EK; Crago AM; Yoon SS; Hwang S; Erinjeri JP; Antonescu CR; Tap WD; D'Angelo SP
Clin Cancer Res; 2023 Jun; 29(11):2043-2051. PubMed ID: 36971773
[TBL] [Abstract] [Full Text] [Related]
20. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Signoretti S; Denize T; Cimadamore A; Wu CJ; Braun D; Einstein D; Catalano PJ; Hammers H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948504
[TBL] [Abstract] [Full Text] [Related]
[Next]
